Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Fiche publication
Date publication
décembre 2017
Journal
The Lancet. Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre
Tous les auteurs :
Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G,
Lien Pubmed
Résumé
Sorafenib is the recommended treatment for patients with advanced hepatocellular carcinoma. We aimed to compare the efficacy and safety of sorafenib to that of selective internal radiotherapy (SIRT) with yttrium-90 (Y) resin microspheres in patients with hepatocellular carcinoma.
Mots clés
Administration, Oral, Adult, Aged, Antineoplastic Agents, administration & dosage, Brachytherapy, methods, Carcinoma, Hepatocellular, drug therapy, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Liver Neoplasms, drug therapy, Male, Microspheres, Middle Aged, Neoplasm Invasiveness, pathology, Neoplasm Staging, Niacinamide, administration & dosage, Phenylurea Compounds, administration & dosage, Radiotherapy Dosage, Survival Analysis, Treatment Outcome, Yttrium Radioisotopes, therapeutic use
Référence
Lancet Oncol.. 2017 Dec;18(12):1624-1636